Abstract
Development of new anticoagulants with targeted inhibition of the coagulation cascade factors, with the possibility of oral administration are certainly in the last 10 years the most important events in KV pharmacotherapy.
Development of new anticoagulants with targeted inhibition of the coagulation cascade factors, with the possibility of oral administration are certainly in the last 10 years the most important events in KV pharmacotherapy.